Australia's Telix gains as Europe accepts brain cancer imaging therapy marketing application

Telix Pharmaceuticals

01/05/2026 02:28

** Shares of Telix Pharmaceuticals TLX.AX rise as much as 3.7% to A$15.55 in early trade, their highest level since April 14

** Biopharma major says marketing authorisation application for its TLX101-Px therapy has been validated and accepted for review in Europe

** TLX101-Px is an imaging candidate for characterisation of glioma, a form of brain cancer

** Says application, which covers commercially significant European markets, has now moved into a 210-day active assessment phase

** Stock up 37.4% YTD, including the day's moves

 (Reporting by Nikita Maria Jino in Bengaluru)

 ((Nikita.Jino@thomsonreuters.com;))